Search
Regeneron Pharmaceuticals Inc
REGNAdd to Watchlist
618.030USD
+5.530+0.90%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
64.89BMarket Cap
14.55P/E TTM
More Details of Regeneron Pharmaceuticals Inc Company
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Regeneron Pharmaceuticals Inc Info
Ticker SymbolREGN
Company nameRegeneron Pharmaceuticals Inc
IPO dateApr 02, 1991
CEOSchleifer (Leonard S)
Number of employees15106
Security typeOrdinary Share
Fiscal year-endApr 02
Address777 Old Saw Mill River Road
CityTARRYTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10591
Phone17813705000
Websitehttps://www.regeneron.com/
Ticker SymbolREGN
IPO dateApr 02, 1991
CEOSchleifer (Leonard S)
Company Executives of Regeneron Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.13M
+0.00%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
688.09K
+0.00%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
52.21K
+0.06%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.31K
-5.98%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.18K
+0.02%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
33.07K
+0.02%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
21.80K
+0.07%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.42K
-0.57%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
14.49K
+0.82%
Dr. Michael S. Brown, M.D.
Dr. Michael S. Brown, M.D.
Independent Director
Independent Director
12.78K
+0.04%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.13M
+0.00%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
688.09K
+0.00%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
52.21K
+0.06%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.31K
-5.98%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.18K
+0.02%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
33.07K
+0.02%
FAQs
Who are the top five shareholders of Regeneron Pharmaceuticals Inc?
The top five shareholders of Regeneron Pharmaceuticals Inc are: Dr. George D. Yancopoulos, M.D., Ph.D
How many institutions hold shares of Regeneron Pharmaceuticals Inc (REGN)?
As of 2026Q1, 2806 institutions hold shares of Regeneron Pharmaceuticals Inc, with a combined market value of approximately 94.67M, accounting for 91.89% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1673066.00.
What is the biggest source of revenue for Regeneron Pharmaceuticals Inc?
In 2026Q1, the Sanofi business generated the highest revenue for Regeneron Pharmaceuticals Inc, amounting to 5.88B and accounting for 41.02% of total revenue.
